普萘洛尔治疗婴幼儿腮腺血管瘤的临床观察

Treatment of infantile parotid hemangioma with propranoiol

目的 评价小剂量普萘洛尔治疗小儿腮腺廊管瘤的临床疗效和安全性。方法17例婴幼儿血管瘤患者按1．0—1．5mg／kg体重口服普萘洛尔，每日1次，连续服用3～5个月。每周复诊，动态观察和记录血管瘤大小、质地、颜色的变化，并随时处理治疗过程中出现的不良反应。按4级评分法对近期疗效进行评价。结果17例随访3～10个月，疗效：Ⅰ级0例，Ⅱ级：0例，Ⅲ级：5例，Ⅳ级：12例。17例均未发生严重不良反应。结论口服小剂量普蔡洛尔治疗婴幼儿增生期腮腺血管瘤近期疗效好，不良反应轻微，普萘洛尔呵作为婴幼儿腮腺血管瘤的一线治疗药物。

Objective To evaluate the short-term results and safety of propranolol for the treatment of infantile parotid hemangioma. Methods Oral propranolol was administered to 17 infants with parotid heamngiom at a dose of 1.0-1.5 mg per kilogram of body weight per day. The patients were revisited once a week. The changes of the tumor size, texture and colour were monitored and recorded at a regular interval. The adverse effects after medication were observed and managed accordingly. The short-term results were evaluated using a 4 scales system. Results Among the 17 patients treated, the follow-up time was 5 to 10 months. The overall response was scale Ⅰ in 0 patient, scale Ⅱ in 0 patients, scale Ⅲ in 5 patients, and seale IV in 12 patients. No serious adverse effects were encountered. Conclusions Oral propranolol at a lower dose is a safe and effective method for the treatment of infantile parotid heamngioma. The short-term results were excellent and the side effects minimal.